Skip to main content

Korsana Biosciences, Inc.

corporate_fare Company Profile

Korsana Biosciences, Inc.

KRSA·NASDAQ·Life Sciences·CIK 0001755237

Korsana Biosciences, Inc. is a biotechnology company focused on developing innovative therapeutics for serious neuropsychiatric disorders with significant unmet medical needs. The company's primary strategic focus is on a novel therapeutic approach for neuropsychiatric conditions, with its lead indication being treatment-resistant depression ("TRD"). Korsana Biosciences, Inc. refines its strategic direction towards programs that combine established pharmacologic agents with enabling technologies to improve precision, reproducibility, and patient outcomes. As part of this strategy, the company has prioritized CYC-126, an individualized therapy for TRD, as its foundational development program. In September 2025, Korsana Biosciences, Inc. entered into a license agreement with the Massachusetts Institute of Technology ("MIT") for intellectual property supporting this program. Under this agreement, MIT is eligible to receive up to $4.4 million upon the achievement of certain development, regulatory, and sales milestone payments. MIT will also receive tiered royalties in a range of percentages in the low single digits based on future net sales of licensed products, and varying percentages of income from any sublicenses granted. In January 2026, the company entered into a collaboration and option-to-license agreement with Medsteer SAS ("Medsteer") to access technology, data assets, and technical know-how related to drug delivery and physiological monitoring. Under this agreement, Korsana Biosciences, Inc. will pay Medsteer a nominal upfront payment, a payment upon exercise of the Option, and Medsteer is eligible to receive up to $3.7 million upon the achievement of certain development, regulatory, and sales milestone payments. Medsteer will also receive an annual royalty payment and royalties in a percentage in the low single digits based on future net sales of licensed products.

Korsana Biosciences, Inc. (NASDAQ:KRSA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 4 items for KRSA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 4 most recent items scored 7 or higher, the top rating is 8/10, with 1 rated 8 or above. Recent SEC coverage for KRSA spans 10-Q, 8-K, PRE 14A.

Recent high-impact activity:

  • Korsana 10-Q: $456.2M Cash Funds Operations Into 2029 After Cyclerion Merger
  • Korsana Posts $46.4M Q3 Loss, $456M Cash Funds Operations Into 2029
  • Korsana Posts $46.4M Q3 Loss, $456.2M Cash Funds Operations Into 2029
  • Korsana Resubmits Cayman Islands Redomestication After Failed Vote, Proposes Classified Board and Exclusive Forum

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$2.07M
Net Income
-$3.53M
Diluted EPS
-$1.11
Op. Cash Flow
-$3.31M
Operating Income
-$4.97M
Cash & Equivalents
$3.24M
Debt / Equity
0.00×
Net Margin
-170.1%
Shares Outstanding
3.82M sh
Source: 10-K · filed 2026-04-30 · accession 0001193125-26-194204

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 167,367 shares in KRSA as of the October 30, 2026 settlement, a 603.1% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 72.2% of KRSA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)167,367 shares as of October 30, 2026
Change vs prior period▲ 603.1%
Days to cover1.00 at avg daily volume of 178,210
Daily short volume (FINRA facilities)72.2% of 114,768 shares on November 20, 2026
5-day average short volume49.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with K →
$37.56
52-week range · as of 2026-11-05 $7.19 – $59.36
Market cap
$1.71B
Volume
265.2K (1.4× avg)
3-mo avg 189.3K
Live data · 2026-11-21 05:27 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed KRSA - Latest Insights

KRSA
Nov 05, 2026, 8:00 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $30.56
Real-time Price: $37.56 info
Change: +$7.00 (+23%) info
Market Cap: $1.711B info
KRSA
Nov 05, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $30.56
Real-time Price: $37.56 info
Change: +$7.00 (+23%) info
Market Cap: $1.711B info
KRSA
Nov 05, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $30.56
Real-time Price: $37.56 info
Change: +$7.00 (+23%) info
Market Cap: $1.711B info
KRSA
Oct 05, 2026, 4:14 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $30.72
Real-time Price: $37.56 info
Change: +$6.84 (+22%) info
Market Cap: $1.711B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets